Depacon (AbbVie Inc.)
Welcome to the PulseAid listing for the Depacon drug offered from AbbVie Inc.. This Anti-epileptic Agent [EPC],Decreased Central Nervous System Disorganized Electrical Activity [PE],Mood Stabilizer [EPC] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
LABELER NAME / MANUFACTURER: | AbbVie Inc. |
NON-PROPRIETARY NAME: | Valproate Sodium |
SUBSTANCE NAME: | VALPROATE SODIUM |
TYPE: | HUMAN PRESCRIPTION DRUG |
PHARMA CLASS: | Anti-epileptic Agent [EPC],Decreased Central Nervous System Disorganized Electrical Activity [PE],Mood Stabilizer [EPC] |
ROUTE: | INTRAVENOUS |
DOSAGE FORM: | INJECTION |
MARKETING CATEGORY NAME: | NDA |
START MARKETING DATE: | 1996-12-30 |
END MARKETING DATE: | 2019-11-01 |
Depacon HUMAN PRESCRIPTION DRUG Details:
Item Description | Depacon from AbbVie Inc. |
LABELER NAME: | AbbVie Inc. |
DEA SCHEDULE: |
|
ACTIVE STRENGTH: | 100(mg/mL) |
START MARKETING DATE: | 1996-12-30 |
END MARKETING DATE: | 2019-11-01 |
PRODUCT ID: | 0074-1564_6fd04f96-6b5e-4cd8-9313-63877dd11f51 |
PRODUCT NDC: | 0074-1564 |
APPLICATION NUMBER: | NDA020593 |
Other VALPROATE SODIUM Pharmaceutical Manufacturers / Labelers: